ClearNote Health will be presenting at the 41st Annual JP Morgan Healthcare Conference

SAN DIEGO–(COMMERCIAL THREAD)–ClearNote Health™ (formerly known as Bluestar Genomics), a cancer tracking company committed to enabling people at risk of high-fatality cancers to live longer, healthier lives, today announced that Chief Executive Officer Dave Mullarkey will present a company update at the 41st Annual JP Morgan Healthcare Conference on Wednesday, January 11 at 2:30pm PST. Mullarkey will speak about the company’s ongoing clinical validation and commercialization efforts in a multi-test portfolio. The Avantect™ portfolio for early cancer detection includes the recently launched pancreatic cancer test, now available for medical order in patients over the age of 50 with type 2 diabetes diagnosed within the past three years.

“Our company has made tremendous progress over the past year in preparing for commercialization of the Avantect pancreatic cancer test, building an international distribution strategy, and planning a multi-product portfolio,” Mullarkey said.This is a game-changer for the company as we turn our focus from validating a single test to developing, validating and commercializing a suite of cancer detection solutions to meet the needs of high-risk cancer patients with limited screening and poor results, including pancreatic and ovarian cancers.

Current trends suggest that pancreatic cancer is poised to become the second leading cause of cancer death within this decade. The Avantect pancreatic cancer test, which received a Breakthrough Device designation from the FDA in 2021, is designed to enable early diagnosis for high-risk patients. Launched in 2022, the test combines the latest capabilities based on epigenomic hydroxymethylation and genomic analysis with machine learning to detect the presence or absence of an abnormal pancreatic cancer signal in blood-free DNA.

Following a successful validation study of the Avantect Pancreatic Cancer Test whose data was presented at the American Pancreatic Association meeting in 2022, the company is currently conducting the New Onset Diabetes Management for Early Detection (NODMED) study, a of the largest clinical trials to date in pancreatic cancer. The multicenter study is currently enrolling patients recently diagnosed with type 2 diabetes, a population with an eight times increased risk of developing pancreatic cancer.

JP Morgan Healthcare conference presentation details

Date: January 11, 2023

Hours: 2:30pm PST

Location: The Westin St. Francis, Mission Bay Room

To learn more about the Avantect Pancreatic Cancer Test, visit avantect.com.

About ClearNote Health

ClearNote Health is a cancer tracking company focused on enabling people at risk of high-fatality cancers to live longer, healthier lives. Using a standard blood sample, the company applies its proprietary epigenomics platform, combining biology and artificial intelligence, to identify DNA-based biological changes as cancer develops. With leading programs in the early noninvasive detection of pancreatic and ovarian cancers in patients at highest risk for these diseases, ClearNote Health identifies cancers before they progress and when patients are most likely to benefit from treatment. ClearNote Health is headquartered in San Diego, with additional presence in the SF Bay area and internationally. The company’s CLIA and CAP accredited laboratory is located in San Diego, California. For more information, visit www.clearnotehealth.com or follow the company at Chirping or LinkedIn.

Leave a Comment

Your email address will not be published. Required fields are marked *